<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002488</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077375</org_study_id>
    <secondary_id>CAN-OTT-9106</secondary_id>
    <secondary_id>NCI-V92-0013</secondary_id>
    <nct_id>NCT00002488</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy</brief_title>
  <official_title>INTENSIFICATION WITH HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN FOR INTERMEDIATE OR HIGH GRADE LYMPHOMA PATIENTS WHO FAILED PRIMARY COMBINATION CHEMOTHERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of&#xD;
      cyclophosphamide, etoposide, and cisplatin in treating patients with intermediate or&#xD;
      high-grade non-Hodgkin's lymphoma who have relapsed following or are resistant to&#xD;
      anthracycline-containing primary combination chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of high-dose cyclophosphamide/etoposide/cisplatin in&#xD;
      patients with intermediate- or high-grade non-Hodgkin's lymphoma who have failed primary&#xD;
      combination chemotherapy but still respond to conventional-dose DHAP&#xD;
      (dexamethasone/cytarabine/cisplatin) and are not candidates for bone marrow transplantation.&#xD;
      II. Determine the toxicity of the intensification chemotherapy regimen in this group of&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: Nonrandomized study. 3-Drug Combination Chemotherapy. CVP: Cyclophosphamide, CTX,&#xD;
      NSC-26271; Etoposide, VP-16, NSC-141540; Cisplatin, CDDP, NSC-119875.&#xD;
&#xD;
      PROJECTED ACCRUAL: If at least 1 CR is seen in the first 6 patients, an estimated maximum of&#xD;
      20 patients will be enrolled. If 3 or more of the first 10 patients (or 25% of the study&#xD;
      population thereafter) die within the first 35 days of treatment from causes unrelated to&#xD;
      tumor progression, the study will be terminated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 1991</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed intermediate- or high-grade non-&#xD;
        Hodgkin's lymphoma of the following histologies: Follicular, predominantly large cell&#xD;
        Diffuse small cleaved cell Diffuse mixed, small and large cell Diffuse large cell Large&#xD;
        cell, immunoblastic Lymphoblastic Small noncleaved cell Disease has relapsed following or&#xD;
        is resistant to primary anthracycline-containing combination chemotherapy Objective&#xD;
        response to salvage DHAP chemotherapy required Ineligible for bone marrow transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 64 Performance status: Zubrod 0 or 1 Hematopoietic: ANC&#xD;
        at least 1,500 Platelets at least 140,000 Hb at least 10 g/dl Hepatic: Bilirubin less than&#xD;
        1.5 mg/dl (26 micromoles/liter) SGOT less than 4 x normal Renal: Creatinine less than 1.5&#xD;
        mg/dl (133 micromoles/liter) Cardiovascular: LVEF greater than 50% No life-threatening&#xD;
        arrhythmia by EKG No uncontrolled hypertension Pulmonary: FEV, FVC, and DLCO greater than&#xD;
        50% of predicted Other: No uncontrolled diabetes No other uncontrolled medical condition No&#xD;
        history of second malignancy except: Nonmelanomatous skin cancer Carcinoma in situ&#xD;
        Effective contraception required of fertile women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior&#xD;
        anthracycline-containing combination chemotherapy required Prior salvage DHAP chemotherapy&#xD;
        required Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not&#xD;
        specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan C. Yau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ottawa Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Center - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2004</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

